ÖZET
Kronik kabızlık, yaygın bir gastrointestinal bozukluktur ve yönetimi genellikle laksatiflerin uzun süreli kullanımını gerektirir. Bu derlemede, yaygın olarak kullanılan iki laksatif olan laktüloz ve bisakodil arasındaki farklılıklar ele alınmıştır. Her iki laksatif etkinlik, yan etki profili, tolerans gelişimi, özel popülasyonlarda kullanım, ilaç etkileşimleri ve kontrendikasyonları, hasta uyumu ve yaşam kalitesi üzerindeki etkileri yönünden var olan kanıtlar ışığından karşılaştırılmıştır. Hem laktüloz hem de bisakodil, bağırsak hareketlerini iyileştirmede etkili olup klinik uygulamada yaygın olarak kullanılırlar. Ancak, yan etki profili, hasta uyumu, yaşam kalitesi ve maliyet-etkinlik gibi faktörler göz önüne alındığında, laktüloz belirli hasta popülasyonları için daha olumlu bir profil sunabilir. Aile hekimleri, hastaları için en uygun tedavi seçeneğini seçerken bu yönleri göz önünde bulundurmalı ve her zaman bireysel hasta özelliklerini ve tercihlerini dikkate almalıdırlar.
References
1
Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106(9):1582-1591; quiz 1581, 1592.
2
American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology 2013;144(1):211-217.
3
Bouhnik Y, Neut C, Raskine L, Michel C, Riottot M, Andrieux C, et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 2004;19(8):889-899.
4
Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2006;23(10):1479-1488.
5
Attar A, Lémann M, Ferguson A, Halphen M, Boutron MC, Flourié B, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999;44(2):226-230.
6
Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015;64(1):84-92.
7
Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57(8):1156-1165.
8
Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol 2003;36(5):386-389.
9
Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010;105(4):897-903.
10
Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ 1993;307(6907):769-771.
11
Mukherjee S, John S. Lactulose. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK536930/
12
Portalatin M, Winstead N. Medical management of constipation. Clin Colon Rectal Surg 2012;25(1):12-19.
13
Kishor C, Ross RL, Blanchard H. Lactulose as a novel template for anti-cancer drug development targeting galectins. Chem Biol Drug Des 2018;92(4):1801-1808.
14
Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011;9(7):577-583.
15
American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100(Suppl 1):S1-4.
16
Lawrensia S, Raja A. Bisacodyl. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547733/
17
Alikiaii B, Majedi MA, Hashemi ST, Kiani M. Comparing the Efficacy of Two Drugs Senalin and Bisacodyl in Treatment of Constipation in Intensive Care Units’ Patients. Adv Biomed Res 2019;8:17.
18
Noergaard M, Traerup Andersen J, Jimenez-Solem E, Bring Christensen M. Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety? Scand J Gastroenterol 2019;54(1):27-34.
19
Lactulose (Oral route). In: MerativeTM Micromedex® Disease - Emergency Medicine (electronic version) [Internet]. Merative, Ann Arbor, Michigan, USA.; Available from: https://www.micromedexsolutions.com/
20
Bisacodyl (Oral route, Rectal route). In: MerativeTM Micromedex® Disease - Emergency Medicine (electronic version) [Internet]. Merative, Ann Arbor, Michigan, USA.; Available from: https://www.micromedexsolutions.com/
21
Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989;84(4):1056-1062.
22
Lindberg G, Hamid S, Malfertheiner P, Thomsen O. World Gastroenterology Organisation Global Guidelines - Constipation: a global perspective [Internet]. World Gastroenterology Organisation; 2010 Nov [cited 2023 May 13]. Available from: https://www.worldgastroenterology.org
23
Mulhem E, Khondoker F, Kandiah S. Constipation in Children and Adolescents: Evaluation and Treatment. Am Fam Physician 2022;105(5):469-478.
24
Southwell BR. Treatment of childhood constipation: a synthesis of systematic reviews and meta-analyses. Expert Rev Gastroenterol Hepatol 2020;14(3):163-174.
25
Li H, Zhang P, Xue Y. A comparison of the safety and efficacy of polyethylene glycol 4000 and lactulose for the treatment of constipation in pregnant women: a randomized controlled clinical study. Ann Palliat Med 2020;9(6):3785-3792.
26
Briggs GG. Brigg’s Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk [Internet]. 12th ed. Lippincott Williams & Wilkins (LWW); 2021 [cited 2023 May 13]. Available from: https://www.wolterskluwer.com/en/solutions/ovid/briggs-drugs-in-pregnancy-and-lactation-a-reference-guide-to-fetal-and-neonatal-risk-730?gclid=CjwKCAjw6vyiBhB_EiwAQJRopiafbXB_xejez3mkASOW0QdzK0rQBMWVSB718y-G2lp-viIWIi3XGxoCx68QAvD_BwE
27
Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023;29(14):2078-2100.
28
Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(Suppl 1):S2-26; quiz S27.
29
Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, et al. Chronic constipation. Nat Rev Dis Primers 2017;3:17095.
30
Romańczuk W, Korczowski R. [Duphalac (lactulose) in the treatment of chronic constipation in children]. Wiad Lek 1995;48(1-12):96-99.
31
Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011;(1):CD003448.
32
Neri L, Basilisco G, Corazziari E, Stanghellini V, Bassotti G, Bellini M, et al. Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterol J 2014;2(2):138-147.
